Application of an improved method for the recombinant K39 enzyme-linked immunosorbent assay to detect visceral leishmaniasis disease and infection in Bangladesh

Clinical and Diagnostic Laboratory Immunology

Volumn 12, Issue 12, 2005, Pages 1410-1415

  Kurkjian, K M ^a   Vaz, L E ^a,d   Haque, R ^b   Cetre Sossah, C ^a,e   Akhter, S ^b   Roy, S ^b   Steurer, F ^a   Amann, J ^a,c   Ali, M ^b   Chowdhury, R ^b   Wagatsuma, Y ^b,f   Williamson, J ^a   Crawford, S ^a   Breiman, R F ^b,g   Maguire, J H ^a,h   Bern, C ^a   Secor, W E ^a,c  

^a NATL CENTER FOR INFECTIOUS DISEASES   (United States)

^b ICDDR B Centre for Health and Population Research   (Bangladesh)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^d VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e CIRAD   (France)

^f UNIVERSITY OF TSUKUBA   (Japan)

^g KENYA MEDICAL RESEARCH INSTITUTE   (Kenya)

^h UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTOZOON ANTIBODY; RECOMBINANT ANTIGEN; RECOMBINANT K39 ANTIGEN; UNCLASSIFIED DRUG;

ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ARTICLE; BANGLADESH; CALCULATION; CHILD; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN TISSUE; LEISHMANIA DONOVANI; LEISHMANIASIS; MAJOR CLINICAL STUDY; PREDICTION; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; REFERENCE VALUE; RELIABILITY; SENSITIVITY AND SPECIFICITY; SYMPTOM; VISCERAL LEISHMANIASIS;

ANIMALS; ANTIBODIES, PROTOZOAN; ANTIGENS, PROTOZOAN; BANGLADESH; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; LEISHMANIA DONOVANI; LEISHMANIASIS, VISCERAL; PROTOZOAN PROTEINS; RECOMBINANT PROTEINS; SENSITIVITY AND SPECIFICITY;

EID: 29144512352     PISSN: 1071412X     EISSN: None     Source Type: Journal    
DOI: 10.1128/CDLI.12.12.1410-1415.2005     Document Type: Article

References (19)

1. Badaro R., T. C. Jones, R. Lorenco, B. J. Cerf, D. Sampaio, E. M. Carvalho, H. Rocha, R. Teixeira, and W. D. Johnson. Jr. 1986. A prospective study of visceral leishmaniasis in an endemic area of Brazil. J. Infect. Dis. 154:639-649.
2. Bern, C., A. W. Hightower, R. Chowdhury, M. Ali, J. Amann, Y. Wagatsuma, R. Haque, K. M. Kurkjian, L. E. Vaz, M. Begum, T. Akter, C. B. Cetre-Sossah, I. Ahluwalia, E. Dotson, W. E. Secor, R. F. Breiman, and J. H. Maguire. 2005. Risk factors for kala-azar in Bangladesh. Emerg. Infect. Dis. 11:655-662.
3. Boelaert, M., S. Rijal, S. Regmi, R. Singh, B. Karki, D. Jacquet, F. Chappuis, L. Campinn, P. Desjeux, D. Le Ray, S. Koirala, and P. Van der Stuyft. 2004. A comparative study of the effectiveness of diagnostic tests for visceral leishmaniasis. Am. J. Trop. Med. Hyg. 70:72-77.
4. Browner, W. S., D. Black, T. B. Newman, and S. B. Hulley. 1988. Estimating sample size and power, p. 139-150. In S. B. Hulley and S. R. Cummings (ed.), Designing clinical research. Williams and Wilkins, Baltimore, MD.
5. Chappuis, F, S. Rijal, R. Singh, P. Acharya, B. M. Karki, M. L. Das, P. A. Bovier, P. Desjeux, D. Le Ray, S. Koirala, and L. Loutan. 2003. Prospective evaluation and comparison of the direct agglutination test and an rK39-antigen-based dipstick test for the diagnosis of suspected kala-azar in Nepal. Trop. Med. Int. Health 8:277-285.
6. Chatterjee, M., C. L. Jaffe, S. Sundar, D. Basu, S. Sen, and C. Mandal. 1999. Diagnostic and prognostic potential of a competitive enzyme-linked immunosorbent assay for leishmaniasis in India. Clin. Diagn. Lab. Immunol. 6:550-554.
7. Chowdhury, M. S., A. el Harith, A. al Massum, E. al Karim, and A. al Rahman. 1993. Prevalence of agglutinating anti-Leishmania antibodies in two multi-thousand Bengali communities. Parasitol. Res. 79:444-450.
8. Desjeux, M. D. 1996. Cutaneous leishmaniasis. Clin. Dermatol. 14:417-423.
9. Houghton, R. L., M. Petrescu, D. R. Benson, Y. A. Skeiky, A. Scalone, and R. Badaro. 1998. A cloned antigen (recombinant K39) of Leishmania chagasi diagnostic for visceral leishmaniasis in human immunodeficiency virus type 1 patients and a prognostic indicator for monitoring patients undergoing drug therapy. J. Infect. Dis. 177:1339-1344.
10. Jacobson, R. H. 1998. Validation of serological assays for diagnosis of infectious diseases. Rev. Sci. Technol. 17:469-526.
11. Kumar, R., K. Pai, K. Pathak, and S. Sundar. 2001. Enzyme-linked immunosorbent assay for recombinant k39 antigen in diagnosis and prognosis of Indian visceral leishmaniasis. Clin. Diagn. Lab. Immunol. 8:1220-1224.
12. Martin-Sanchez, J., J. A. Pineda, F. Morillas-Marquez, J. A. Garcia-Garcia, C. Acedo, and J. Macias. 2004. Detection of Leishmania infantum kinetoplast DNA in peripheral blood from asymptomatic individuals at risk for parenterally transmitted infections: relationship between polymerase chain reaction results and other Leishmania infection markers. Am. J. Trop. Med. Hyg. 70:545-548.
13. Pearson, R., and A. Q. Sousa. 1996. Clinical spectrum of leishmanisasis. Clin. Infect. Dis. 22:1-13.
14. Sundar, S., and M. Rai. 2002. Laboratory diagnosis of visceral leishmaniasis. Clin. Diagn. Lab. Immunol. 9:951-958.
15. World Health Organization. 2002. World Health Report 2002 statistical annex. [Online.] http://www.who.int/whr/2002/en/whr2002_annex2.pdf.
16. World Health Organization. 2004. Leishmaniasis: disease information. [Online.] http://www.who.int/tdr/diseases/leish/diseaseinfo.htm.
17. Zijlstra, E. E., N. S. Daifalla, P. A. Kager, E. A. Khalil, A. M. El-Hassan, S. G. Reed, and H. W. Ghalib. 1998. rK39 enzyme-linked immunosorbent assay for diagnosis of Leishmania donovani infection. Clin. Diagn. Lab. Immunol. 5:717-720.
18. Zijlstra, E. E., O. F. Osman, H. W. Hofland, L. Oskam, H. W. Ghalib, A. M. el-Hassan, P. A. Kager, and S. E. Meredith. 1997. The direct agglutination test for diagnosis of visceral leishmaniasis under field conditions in Sudan: comparison of aqueous and freeze-dried antigens. Trans. R. Soc. Trop. Med. Hyg. 91:671-673.
19. Zweig, M. H., and G. Campbell. 1993. Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin. Chem. 39:561-577.